Merck's massive cardio study keeps rolling as fallen rivals pile up

[frothmouth]

“Merck ($MRK), the last Big Pharma standing in CETP inhibition, is pressing forward with a huge cardiovascular trial after getting the green light from its independent advisers, stepping over the scattered failures of similar projects in hopes of hitting upon a blockbuster. The drug, anacetrapib,